Article
Predicting the response of CML patients to tyrosine kinase inhibitor therapy.
Current hematologic malignancy reports - 1 Jun 2011
White Deborah L, Hughes Timothy P
Abstract excerpt
As of 2011, the choice of tyrosine kinase inhibitor (TKI) for the patient with newly diagnosed chronic-phase chronic myelogenous leukemia (CP-CML) is no longer limited to imatinib but can be expanded to include nilotinib and dasatinib. Since 2000, imatinib has demonstrated remarkable efficacy in the majority of chronic-phase patients. Nilotinib and dasatinib, both more potent TKIs, are likely to produce quicker...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.